# Allegro Microsystems, Inc.: financial statements, quarterly ALGM · Nasdaq · CIK 866291 · [Technology](/sectors/technology.md) · fiscal year ends Mar 31 Pages: [Overview](/companies/algm.md) · [Financials](/companies/algm/financials.md) · [Filings](/companies/algm/filings.md) · [Insiders](/companies/algm/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/algm/financials.md?period=annual). ## Income statement | Line item | Unit | Q2 FY2024 (2023-09-29) | Q3 FY2024 (2023-12-29) | Q4 FY2024 (2024-03-29) | Q1 FY2025 (2024-06-28) | Q2 FY2025 (2024-09-27) | Q3 FY2025 (2024-12-27) | Q4 FY2025 (2025-03-28) | Q1 FY2026 (2025-06-27) | Q2 FY2026 (2025-09-26) | Q3 FY2026 (2025-12-26) | Q4 FY2026 (2026-03-27) | Q1 FY2027 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [276](/filings/0000950170-24-119808.md) | [255](/filings/0000950170-25-011434.md) | [241 d](/filings/0001193125-26-233537.md) | [167](/filings/0000950170-25-101117.md) | [187](/filings/0001193125-25-259807.md) | [178](/filings/0001193125-26-030636.md) | [193](/filings/0000950170-25-101117.md) | [203](/filings/0001193125-26-327128.md) | [214](/filings/0001193125-25-259807.md) | [229](/filings/0001193125-26-030636.md) | [243 d](/filings/0001193125-26-233537.md) | [259](/filings/0001193125-26-327128.md) | | Cost of revenue | $m | [114](/filings/0000950170-24-119808.md) | [121](/filings/0000950170-25-011434.md) | [117 d](/filings/0001193125-26-233537.md) | [92.1](/filings/0000950170-25-101117.md) | [102](/filings/0001193125-25-259807.md) | [96.7](/filings/0001193125-26-030636.md) | [113 d](/filings/0001193125-26-233537.md) | [112](/filings/0001193125-26-327128.md) | [115](/filings/0001193125-25-259807.md) | [122](/filings/0001193125-26-030636.md) | [129 d](/filings/0001193125-26-233537.md) | [134](/filings/0001193125-26-327128.md) | | Gross profit | $m | [160](/filings/0000950170-24-119808.md) | [134](/filings/0000950170-25-011434.md) | [123 d](/filings/0001193125-26-233537.md) | [74.8](/filings/0000950170-25-101117.md) | [85.7](/filings/0001193125-25-259807.md) | [81.2](/filings/0001193125-26-030636.md) | [79.9 d](/filings/0001193125-26-233537.md) | [91.3](/filings/0001193125-26-327128.md) | [99.3](/filings/0001193125-25-259807.md) | [107](/filings/0001193125-26-030636.md) | [114 d](/filings/0001193125-26-233537.md) | [126](/filings/0001193125-26-327128.md) | | Research and development | $m | [43.4](/filings/0000950170-24-119808.md) | [44.4](/filings/0000950170-25-011434.md) | [45.8 d](/filings/0001193125-26-233537.md) | [45.2](/filings/0000950170-25-101117.md) | [43.5](/filings/0001193125-25-259807.md) | [43.3](/filings/0001193125-26-030636.md) | [47.6 d](/filings/0001193125-26-233537.md) | [46.5](/filings/0001193125-26-327128.md) | [50.9](/filings/0001193125-25-259807.md) | [52.9](/filings/0001193125-26-030636.md) | [55.5 d](/filings/0001193125-26-233537.md) | [55.2](/filings/0001193125-26-327128.md) | | Selling, general and administrative | $m | [43.2](/filings/0000950170-24-119808.md) | [52.7](/filings/0000950170-25-011434.md) | [48.3 d](/filings/0001193125-26-233537.md) | [40.2](/filings/0000950170-25-101117.md) | [38.1](/filings/0001193125-25-259807.md) | [37.9](/filings/0001193125-26-030636.md) | [45.5 d](/filings/0001193125-26-233537.md) | [47.5](/filings/0001193125-26-327128.md) | [42.2](/filings/0001193125-25-259807.md) | [44.6](/filings/0001193125-26-030636.md) | [46.7 d](/filings/0001193125-26-233537.md) | [45.0](/filings/0001193125-26-327128.md) | | Operating income | $m | [72.9](/filings/0000950170-24-119808.md) | [36.7](/filings/0000950170-25-011434.md) | [15.9 d](/filings/0001193125-26-233537.md) | [(10.6)](/filings/0000950170-25-101117.md) | [4.1](/filings/0001193125-25-259807.md) | [(0.0)](/filings/0001193125-26-030636.md) | [(13.2) d](/filings/0001193125-26-233537.md) | [(2.7)](/filings/0001193125-26-327128.md) | [6.2](/filings/0001193125-25-259807.md) | [9.6](/filings/0001193125-26-030636.md) | [5.4 d](/filings/0001193125-26-233537.md) | [25.5](/filings/0001193125-26-327128.md) | | Interest expense | $m | [0.8](/filings/0000950170-24-119808.md) | [3.9](/filings/0000950170-25-011434.md) | [5.4 d](/filings/0001193125-26-233537.md) | [5.4](/filings/0000950170-25-101117.md) | [10.4](/filings/0001193125-25-259807.md) | [7.8](/filings/0001193125-26-030636.md) | [6.9 d](/filings/0001193125-26-233537.md) | [6.4](/filings/0001193125-26-327128.md) | [5.7](/filings/0001193125-25-259807.md) | [4.9](/filings/0001193125-26-030636.md) | [5.1 d](/filings/0001193125-26-233537.md) | [4.4](/filings/0001193125-26-327128.md) | | Income tax | $m | [7.4](/filings/0000950170-24-119808.md) | [3.0](/filings/0000950170-25-011434.md) | [24.3 d](/filings/0001193125-26-233537.md) | [1.0](/filings/0000950170-25-101117.md) | [(9.5)](/filings/0001193125-25-259807.md) | [(0.8)](/filings/0001193125-26-030636.md) | [(3.7) d](/filings/0001193125-26-233537.md) | [3.2](/filings/0001193125-26-327128.md) | [(9.3)](/filings/0001193125-25-259807.md) | [(7.9)](/filings/0001193125-26-030636.md) | [13.7 d](/filings/0001193125-26-233537.md) | [1.5](/filings/0001193125-26-327128.md) | | Net income | $m | [65.6](/filings/0000950170-24-119808.md) | [33.3](/filings/0000950170-25-011434.md) | [(7.1) d](/filings/0001193125-26-233537.md) | [(17.7)](/filings/0000950170-25-101117.md) | [(33.7)](/filings/0001193125-25-259807.md) | [(6.9)](/filings/0001193125-26-030636.md) | [(14.8) d](/filings/0001193125-26-233537.md) | [(13.2)](/filings/0001193125-26-327128.md) | [6.5](/filings/0001193125-25-259807.md) | [8.3](/filings/0001193125-26-030636.md) | [(16.5) d](/filings/0001193125-26-233537.md) | [15.9](/filings/0001193125-26-327128.md) | | Diluted EPS | $ per share | [0.34](/filings/0000950170-24-119808.md) | [0.17](/filings/0000950170-25-011434.md) | not reported | [(0.09)](/filings/0000950170-25-101117.md) | [(0.18)](/filings/0001193125-25-259807.md) | [(0.04)](/filings/0001193125-26-030636.md) | not reported | [(0.07)](/filings/0001193125-26-327128.md) | [0.03](/filings/0001193125-25-259807.md) | [0.04](/filings/0001193125-26-030636.md) | not reported | [0.08](/filings/0001193125-26-327128.md) | | Basic EPS | $ per share | [0.34](/filings/0000950170-24-119808.md) | [0.17](/filings/0000950170-25-011434.md) | not reported | [(0.09)](/filings/0000950170-25-101117.md) | [(0.18)](/filings/0001193125-25-259807.md) | [(0.04)](/filings/0001193125-26-030636.md) | not reported | [(0.07)](/filings/0001193125-26-327128.md) | [0.04](/filings/0001193125-25-259807.md) | [0.04](/filings/0001193125-26-030636.md) | not reported | [0.09](/filings/0001193125-26-327128.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q2 FY2024 (2023-09-29) | Q3 FY2024 (2023-12-29) | FY2024 (2024-03-29) | Q1 FY2025 (2024-06-28) | Q2 FY2025 (2024-09-27) | Q3 FY2025 (2024-12-27) | FY2025 (2025-03-28) | Q1 FY2026 (2025-06-27) | Q2 FY2026 (2025-09-26) | Q3 FY2026 (2025-12-26) | FY2026 (2026-03-27) | Q1 FY2027 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [370](/filings/0000950170-23-059019.md) | [214](/filings/0000950170-24-011712.md) | [212](/filings/0001193125-26-233537.md) | [173](/filings/0000950170-24-089610.md) | [189](/filings/0000950170-24-119808.md) | [138](/filings/0000950170-25-011434.md) | [121](/filings/0001193125-26-233537.md) | [129](/filings/0000950170-25-101117.md) | [117](/filings/0001193125-25-259807.md) | [155](/filings/0001193125-26-030636.md) | [169](/filings/0001193125-26-327128.md) | [162](/filings/0001193125-26-327128.md) | | Current assets | $m | [715](/filings/0000950170-23-059019.md) | [549](/filings/0000950170-24-011712.md) | [572](/filings/0000950170-25-076059.md) | [490](/filings/0000950170-24-089610.md) | [524](/filings/0000950170-24-119808.md) | [496](/filings/0000950170-25-011434.md) | [483](/filings/0001193125-26-233537.md) | [447](/filings/0000950170-25-101117.md) | [469](/filings/0001193125-25-259807.md) | [515](/filings/0001193125-26-030636.md) | [504](/filings/0001193125-26-327128.md) | [508](/filings/0001193125-26-327128.md) | | Total assets | $m | [1,285](/filings/0000950170-23-059019.md) | [1,565](/filings/0000950170-24-011712.md) | [1,531](/filings/0000950170-25-076059.md) | [1,449](/filings/0000950170-24-089610.md) | [1,492](/filings/0000950170-24-119808.md) | [1,442](/filings/0000950170-25-011434.md) | [1,421](/filings/0001193125-26-233537.md) | [1,389](/filings/0000950170-25-101117.md) | [1,384](/filings/0001193125-25-259807.md) | [1,423](/filings/0001193125-26-030636.md) | [1,416](/filings/0001193125-26-327128.md) | [1,412](/filings/0001193125-26-327128.md) | | Current liabilities | $m | [134](/filings/0000950170-23-059019.md) | [120](/filings/0000950170-24-011712.md) | [118](/filings/0000950170-25-076059.md) | [106](/filings/0000950170-24-089610.md) | [124](/filings/0000950170-24-119808.md) | [101](/filings/0000950170-25-011434.md) | [112](/filings/0001193125-26-233537.md) | [121](/filings/0000950170-25-101117.md) | [121](/filings/0001193125-25-259807.md) | [141](/filings/0001193125-26-030636.md) | [146](/filings/0001193125-26-327128.md) | [137](/filings/0001193125-26-327128.md) | | Total liabilities | $m | [187](/filings/0000950170-23-059019.md) | [430](/filings/0000950170-24-011712.md) | [399](/filings/0000950170-25-076059.md) | [339](/filings/0000950170-24-089610.md) | [553](/filings/0000950170-24-119808.md) | [507](/filings/0000950170-25-011434.md) | [490](/filings/0001193125-26-233537.md) | [465](/filings/0000950170-25-101117.md) | [438](/filings/0001193125-25-259807.md) | [458](/filings/0001193125-26-030636.md) | [460](/filings/0001193125-26-327128.md) | [446](/filings/0001193125-26-327128.md) | | Long-term debt | $m | not reported | [250](/filings/0000950170-24-011712.md) | [250](/filings/0000950170-25-076059.md) | [203](/filings/0000950170-24-089610.md) | [396](/filings/0000950170-24-119808.md) | [375](/filings/0000950170-25-011434.md) | [345](/filings/0001193125-26-233537.md) | [311](/filings/0000950170-25-101117.md) | [286](/filings/0001193125-25-259807.md) | [286](/filings/0001193125-26-030636.md) | [286](/filings/0001193125-26-327128.md) | [286](/filings/0001193125-26-327128.md) | | Current portion of debt | $m | not reported | [4.0](/filings/0000950170-24-011712.md) | [3.9](/filings/0000950170-25-076059.md) | [1.4](/filings/0000950170-24-089610.md) | [5.5](/filings/0000950170-24-119808.md) | [1.4](/filings/0000950170-25-011434.md) | [1.4](/filings/0001193125-26-233537.md) | [1.5](/filings/0000950170-25-101117.md) | [1.6](/filings/0001193125-25-259807.md) | [1.6](/filings/0001193125-26-030636.md) | [1.5](/filings/0001193125-26-327128.md) | [1.5](/filings/0001193125-26-327128.md) | | Shareholders' equity | $m | [1,097](/filings/0000950170-23-059019.md) | [1,134](/filings/0000950170-24-011712.md) | [1,130](/filings/0000950170-25-076059.md) | [1,109](/filings/0000950170-24-089610.md) | [937](/filings/0000950170-24-119808.md) | [933](/filings/0000950170-25-011434.md) | [930](/filings/0001193125-26-233537.md) | [923](/filings/0000950170-25-101117.md) | [944](/filings/0001193125-25-259807.md) | [963](/filings/0001193125-26-030636.md) | [955](/filings/0001193125-26-327128.md) | [964](/filings/0001193125-26-327128.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q2 FY2024 (2023-09-29) | Q3 FY2024 (2023-12-29) | Q4 FY2024 (2024-03-29) | Q1 FY2025 (2024-06-28) | Q2 FY2025 (2024-09-27) | Q3 FY2025 (2024-12-27) | Q4 FY2025 (2025-03-28) | Q1 FY2026 (2025-06-27) | Q2 FY2026 (2025-09-26) | Q3 FY2026 (2025-12-26) | Q4 FY2026 (2026-03-27) | Q1 FY2027 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [46.7 d](/filings/0000950170-24-119808.md) | [72.6 d](/filings/0000950170-25-011434.md) | [12.8 d](/filings/0001193125-26-233537.md) | [34.2](/filings/0000950170-25-101117.md) | [15.5 d](/filings/0001193125-25-259807.md) | [(8.2) d](/filings/0001193125-26-030636.md) | [20.4 d](/filings/0001193125-26-233537.md) | [61.6](/filings/0001193125-26-327128.md) | [20.4 d](/filings/0001193125-25-259807.md) | [45.4 d](/filings/0001193125-26-030636.md) | [35.7 d](/filings/0001193125-26-233537.md) | [22.0](/filings/0001193125-26-327128.md) | | Capital expenditure | $m | [31.2 d](/filings/0000950170-24-119808.md) | [34.4 d](/filings/0000950170-25-011434.md) | [14.3 d](/filings/0001193125-26-233537.md) | [11.0](/filings/0000950170-25-101117.md) | [10.0 d](/filings/0001193125-25-259807.md) | [13.6 d](/filings/0001193125-26-030636.md) | [5.4 d](/filings/0001193125-26-233537.md) | [10.6](/filings/0001193125-26-327128.md) | [6.4 d](/filings/0001193125-25-259807.md) | [4.1 d](/filings/0001193125-26-030636.md) | [17.0 d](/filings/0001193125-26-233537.md) | [8.0](/filings/0001193125-26-327128.md) | | Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Share repurchases | $m | not reported | [0.0 d](/filings/0000950170-25-011434.md) | [0.0 d](/filings/0001193125-26-233537.md) | not reported | not reported | [0.1 d](/filings/0001193125-26-030636.md) | [0.0 d](/filings/0001193125-26-233537.md) | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: not reported - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q2 FY2023 (2022-09-23) | Q3 FY2023 (2022-12-23) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-29) | Q3 FY2024 (2023-12-29) | Q1 FY2025 (2024-06-28) | Q2 FY2025 (2024-09-27) | Q3 FY2025 (2024-12-27) | Q1 FY2026 (2025-06-27) | Q2 FY2026 (2025-09-26) | Q3 FY2026 (2025-12-26) | Q1 FY2027 (2026-06-26) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [193](/filings/0000950170-23-059019.md) | [194](/filings/0000950170-24-011712.md) | [195](/filings/0000950170-24-089610.md) | [195](/filings/0000950170-24-119808.md) | [195](/filings/0000950170-25-011434.md) | [193](/filings/0000950170-25-101117.md) | [189](/filings/0001193125-25-259807.md) | [184](/filings/0001193125-26-030636.md) | [185](/filings/0001193125-26-327128.md) | [186](/filings/0001193125-25-259807.md) | [186](/filings/0001193125-26-030636.md) | [188](/filings/0001193125-26-327128.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 186,402,046 at 2026-07-27, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-327128.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.